MVP

Across TCGA pan-cancer cohorts, MVP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MVP data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MVP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MVP expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

LSCC, GBM, and PDAC are the cancer types where MVP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.513	0.939	.005	23	view →
GBM	DFS	Median	All	0.632	0.860	.002	18	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →
HNSC	DFS	Quartile	III,IV	0.832	0.331	.024	2	view →
LUAD	OS	Median	III,IV	0.861	0.384	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MVP–LSCC (DFS)

Open the LSCC breakdown →